366 related articles for article (PubMed ID: 16673410)
1. Minimal clinically important change on the unified Parkinson's disease rating scale.
Schrag A; Sampaio C; Counsell N; Poewe W
Mov Disord; 2006 Aug; 21(8):1200-7. PubMed ID: 16673410
[TBL] [Abstract][Full Text] [Related]
2. The clinically important difference on the unified Parkinson's disease rating scale.
Shulman LM; Gruber-Baldini AL; Anderson KE; Fishman PS; Reich SG; Weiner WJ
Arch Neurol; 2010 Jan; 67(1):64-70. PubMed ID: 20065131
[TBL] [Abstract][Full Text] [Related]
3. Determination of minimal clinically important change in early and advanced Parkinson's disease.
Hauser RA; Auinger P;
Mov Disord; 2011 Apr; 26(5):813-8. PubMed ID: 21437987
[TBL] [Abstract][Full Text] [Related]
4. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
LeWitt P; Oakes D; Cui L
Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
[TBL] [Abstract][Full Text] [Related]
5. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
6. Rating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's Disease Rating Scale.
van Hilten JJ; van der Zwan AD; Zwinderman AH; Roos RA
Mov Disord; 1994 Jan; 9(1):84-8. PubMed ID: 8139609
[TBL] [Abstract][Full Text] [Related]
7. Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.
Tison F; Yekhlef F; Chrysostome V; Balestre E; Quinn NP; Poewe W; Wenning GK
Mov Disord; 2002 Jul; 17(4):701-9. PubMed ID: 12210859
[TBL] [Abstract][Full Text] [Related]
8. Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial.
Siderowf A; McDermott M; Kieburtz K; Blindauer K; Plumb S; Shoulson I;
Mov Disord; 2002 Jul; 17(4):758-63. PubMed ID: 12210871
[TBL] [Abstract][Full Text] [Related]
9. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
10. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials.
Rabey JM; Bass H; Bonuccelli U; Brooks D; Klotz P; Korczyn AD; Kraus P; Martinez-Martin P; Morrish P; Van Sauten W; Van Hilten B
Clin Neuropharmacol; 1997 Aug; 20(4):322-37. PubMed ID: 9260730
[TBL] [Abstract][Full Text] [Related]
12. Factor structure of the Unified Parkinson's Disease Rating Scale: Motor Examination section.
Stebbins GT; Goetz CG
Mov Disord; 1998 Jul; 13(4):633-6. PubMed ID: 9686766
[TBL] [Abstract][Full Text] [Related]
13. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
Buchwald B; Angersbach D; Jost WH
Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
[TBL] [Abstract][Full Text] [Related]
14. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
[TBL] [Abstract][Full Text] [Related]
16. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A;
Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922
[TBL] [Abstract][Full Text] [Related]
17. Effect of ropinirole on visuo-motor test in newly diagnosed Parkinson's disease patients.
Badarny S; Stern A; Susel Z; Honigman S; Hocherman S
Acta Neurol Scand; 2006 May; 113(5):294-300. PubMed ID: 16629764
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.
Tompson D; Oliver-Willwong R
Clin Neuropharmacol; 2009; 32(3):140-8. PubMed ID: 18978485
[TBL] [Abstract][Full Text] [Related]
19. Effects of dopaminergic treatment on bladder function in Parkinson's disease.
Winge K; Werdelin LM; Nielsen KK; Stimpel H
Neurourol Urodyn; 2004; 23(7):689-96. PubMed ID: 15382192
[TBL] [Abstract][Full Text] [Related]
20. Surgery for Parkinson's disease improves disability but not impairment components of the UPDRS-II.
Haffenden A; Khan U; Kiss ZH; Suchowersky O
Parkinsonism Relat Disord; 2007 Oct; 13(7):399-405. PubMed ID: 17368072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
